These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
154 related items for PubMed ID: 2554100
1. Ifosfamide and mesna. Med Lett Drugs Ther; 1989 Nov 03; 31(804):98-9. PubMed ID: 2554100 [No Abstract] [Full Text] [Related]
2. Nursing implications in the administration of ifosfamide and mesna. Richters JE. Oncol Nurs Forum; 1990 Nov 03; 17(2):276. PubMed ID: 2107534 [No Abstract] [Full Text] [Related]
3. [Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna]. Matsumoto S, Kawaguchi N, Manabe J, Kuroda H, Shimoji T. Gan To Kagaku Ryoho; 1995 Jun 03; 22(7):965-8. PubMed ID: 7794006 [No Abstract] [Full Text] [Related]
4. The role of ifosfamide in the treatment of nonseminomatous testicular cancer. Scheulen ME, Niederle N, Kath R, Wandl UB, Seeber S, Schmidt CG. Prog Clin Biol Res; 1988 Jun 03; 269():439-50. PubMed ID: 2455912 [No Abstract] [Full Text] [Related]
5. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Semin Oncol; 1996 Jun 03; 23(3 Suppl 6):97-8. PubMed ID: 8677458 [Abstract] [Full Text] [Related]
6. Oral administration of mesna with ifosfamide. Goren MP. Semin Oncol; 1996 Jun 03; 23(3 Suppl 6):91-6. PubMed ID: 8677457 [Abstract] [Full Text] [Related]
7. Germ-cell tumors. Kondagunta V, Galsky MD, Sonpavde G. N Engl J Med; 2007 Oct 25; 357(17):1773; author reply 1773-4. PubMed ID: 17969229 [No Abstract] [Full Text] [Related]
9. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. Sakurai M, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Sano T, Suemasu K, Jett JR. Jpn J Clin Oncol; 1986 Jun 25; 16(2):153-6. PubMed ID: 3090314 [Abstract] [Full Text] [Related]
10. Ifosfamide and Mesna in advanced malignancies. Li GC, Brock N, Li JQ, Guan ZZ, He YJ. Chin Med J (Engl); 1988 Mar 25; 101(3):213-20. PubMed ID: 3136996 [No Abstract] [Full Text] [Related]
11. High-dose chemotherapy in nonseminomatous germ cell cancer. Kollmannsberger C, Beyer J, Bokemeyer C. BJU Int; 2009 Nov 25; 104(9 Pt B):1398-403. PubMed ID: 19840020 [No Abstract] [Full Text] [Related]
12. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. Andriole GL, Sandlund JT, Miser JS, Arasi V, Linehan M, Magrath IT. J Clin Oncol; 1987 May 25; 5(5):799-803. PubMed ID: 3106585 [Abstract] [Full Text] [Related]
13. Dramatic response to ifosfamide, mesna and doxorubicin chemotherapy regimen in an adult with clear cell sarcoma of the kidney. Yalçin S, Barişta I, Tekuzman G, Güllü I, Firat D. J Urol; 1996 Jun 25; 155(6):2024. PubMed ID: 8618315 [No Abstract] [Full Text] [Related]
14. Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO). Frustaci S, Foladore S, De Pascale A, Freschi A, Lo Re G, Sorio R, Errante D, Monfardini S. Ann Oncol; 1992 Apr 25; 3 Suppl 2():S115-8. PubMed ID: 1622852 [Abstract] [Full Text] [Related]